The Federal Trade Commission is requiring the sale of Eli Lilly's Sentinel heartworm products because the Novartis deal would reduce competition and lead to higher prices. Eli Lilly will sell Sentinel to French pharmaceutical company Virbac.
Shares of Achillion Pharmaceuticals advanced after the company said a combination of two...
Roche has announced the acquisition of Bina Technologies, a privately held company based in...
The Biomedical Advanced Research and Development Authority of the United States Department of...
Sartorius, an international laboratory and pharmaceutical equipment provider, is selling its Industrial Technologies Division (Intec) to the Japanese Minebea Co., Ltd. (Minebea) and their partner, the Development Bank of Japan Inc.
A federal judge on Friday ordered home confinement and GPS monitoring for two former officials with a now-defunct Massachusetts compounding pharmacy at the center of a 2012 fungal meningitis outbreak that killed 64 people and sickened more than 750 others across the country.
The nation's largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a drug from AbbVie while pulling back on those from rival drugmakers.
Bayer HealthCare and Cardinal Health have signed a 15-year agreement for the contract manufacturing of Xofigo. As part of the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo.
The Watertown, Massachusetts, company said eravacycline proved to be not inferior to a competing drug, ertapenem, and patients taking it had no serious, drug-related side effects, according to early results from the study.
The grants awarded by the Colorado Board of Health will go to studies on whether marijuana helps treat epilepsy, brain tumors, Parkinson's disease and post-traumatic stress disorder. Some of the studies still need federal approval.
Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.
A federal judge dismissed a lawsuit by 1,300 former players against the NFL, writing that the collective bargaining agreement between the league and the union was the appropriate forum to resolve claims that teams damaged the players' by routinely dispensing painkillers.
Earlier this week, President Barack Obama signed into law a little piece of legislation that may significantly change the economics of making drugs or vaccines to protect against Ebola and other viruses in its deadly family.
Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.
United Therapeutics Corporation has announced two senior executive promotions as well as changes to Martine Rothblatt, Ph.D's compensation program.
Fourteen owners or employees of a Massachusetts pharmacy were charged Wednesday in connection with a 2012 meningitis outbreak that killed 64 people nationwide and was traced to tainted drug injections.
Halozyme Therapeutics has entered into a worldwide collaboration and license agreement with Janssen Biotech for the purpose of developing and commercializing products combining proprietary Janssen compounds with Halozyme's ENHANZE technology.
Napster co-founder Sean Parker says he missed most of his final year in high school and has ended up in the emergency room countless of times because of his deadly allergy to nuts, shellfish and other foods.
The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year, according to research and consulting firm GlobalData.
Lilly has been dealing with a drop in both earnings and revenue due to the loss of patents protecting key drugs from cheaper generic competition. Company executives have said they remained committed to the dividend, despite the financial blows the company was absorbing, but some analysts have questioned whether that commitment might waver.
Pharmaceutical Product Development and ERT today announced a strategic partnership to facilitate delivery of ERT’s comprehensive solutions for patient safety and efficacy endpoint data collection to help biopharmaceutical clients conduct clinical trials in a more efficient and cost-effective manner.
U.S. District Judge Robert Sweet told Dublin-based Actavis PLC to continue making the drug Namenda available for 30 days after generic alternatives become available on July 11 "in order to allow for an orderly transition."
Actavis has announced the planned senior management team that will lead the global pharmaceutical company following the successful close of the acquisition of Allergan anticipated in the second quarter of 2015.
Actavis confirmed that it is filing an emergency appeal to the U.S. Court of Appeals for the Second Circuit seeking to immediately overturn a lower court ruling requiring the Company to continue distribution of NAMENDA (memantine HCl) immediate-release tablets.
The justices left in place a lower court ruling that blocked rules that regulate where and how women can take drugs that induce abortion. The rules also would prohibit the use of the abortion medications after the seventh week of pregnancy instead of the ninth.
A wave of corporate mega deal activity drove a significant uptick in M&A value in 2014, according to PwC US. As businesses aim to meet their growth ambitions and increase market share, PwC expects there will be more attractive opportunities for dealmakers to acquire, combine and align with strategic partners in 2015.
Gilead Sciences has announced that Philippe C. Bishop, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutics. In this position, Dr. Bishop will report to John McHutchison, MD, Executive Vice President, Clinical Research.
Scientists often test drugs in mice. Now some cancer patients are doing the same — with the hope of curing their own disease. They are paying a private lab to breed mice that carry bits of their own tumors so treatments can be tried first on the customized rodents.
- Page 1